Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hoffmann

Showing results (291-300 of 312) with videos related to

Pageof 32
Sort By:
Cell Reports. Medicine|November 9, 2020
Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial CellsAlexander Carpinteiro, Michael J Edwards, Markus Hoffmann, et al.
Nature Immunology|January 20, 2015
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivoAlexander Ulges, Matthias Klein, Sebastian Reuter, et al.
Biorxiv : the Preprint Server for Biology|June 16, 2021
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cellsMatthew Mahoney, Vishnu C Damalanka, Michael A Tartell, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2021
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cellsMatthew Mahoney, Vishnu C Damalanka, Michael A Tartell, et al.
Scientific Reports|November 18, 2022
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinationsHenning Jacobsen, Monika Strengert, Henrike Maaß, et al.
Nature Communications|August 18, 2022
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Georg M N Behrens, Joana Barros-Martins, Anne Cossmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 2, 2025
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodiesOhan Mazigi, David B Langley, Jake Y Henry, et al.
Nature Microbiology|July 25, 2020
LY6E impairs coronavirus fusion and confers immune control of viral diseaseStephanie Pfaender, Katrina B Mar, Eleftherios Michailidis, et al.
Nature Communications|March 20, 2021
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infectionLukas Wettstein, Tatjana Weil, Carina Conzelmann, et al.
The Lancet. Oncology|February 16, 2023
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysisHisham Mehanna, Miren Taberna, Christian von Buchwald, et al.
Pageof 32

Showing results (291-300 of 312) with videos related to

Sort By:
Pageof 32
Cell Reports. Medicine|November 9, 2020
Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial CellsAlexander Carpinteiro, Michael J Edwards, Markus Hoffmann, et al.
Nature Immunology|January 20, 2015
Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivoAlexander Ulges, Matthias Klein, Sebastian Reuter, et al.
Biorxiv : the Preprint Server for Biology|June 16, 2021
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cellsMatthew Mahoney, Vishnu C Damalanka, Michael A Tartell, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2021
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cellsMatthew Mahoney, Vishnu C Damalanka, Michael A Tartell, et al.
Scientific Reports|November 18, 2022
Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinationsHenning Jacobsen, Monika Strengert, Henrike Maaß, et al.
Nature Communications|August 18, 2022
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Georg M N Behrens, Joana Barros-Martins, Anne Cossmann, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 2, 2025
Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodiesOhan Mazigi, David B Langley, Jake Y Henry, et al.
Nature Microbiology|July 25, 2020
LY6E impairs coronavirus fusion and confers immune control of viral diseaseStephanie Pfaender, Katrina B Mar, Eleftherios Michailidis, et al.
Nature Communications|March 20, 2021
Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infectionLukas Wettstein, Tatjana Weil, Carina Conzelmann, et al.
The Lancet. Oncology|February 16, 2023
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysisHisham Mehanna, Miren Taberna, Christian von Buchwald, et al.
Pageof 32